The significant positive associations observed between tumour levels of TGFB2, TGFB3 and TGFBR2 mRNA and clinical outcomes in patients diagnosed with lymph node-negative diseases implicated that the majority of the tumours from those patients still responded to the suppressive effect of TGFβ signalling, and the tumours with lower TGFB2, TGFB3 and TGFBR2 expression were more advantageous in tumour progression. The gene discussed is TGFBR2; the disease is neoplasm.